skip to main content

HCV DAA Treatment Failure — RACP Adult Medicine MCQ

Instant feedback + full explanation. One question, done properly.

HardGastroenterologyHCV DAA Treatment FailureRACP Adult Medicine

A 45-year-old woman with chronic HCV (genotype 3) failed a previous course of sofosbuvir/velpatasvir. She has compensated cirrhosis. NS5A resistance testing shows Y93H mutation. What is the most appropriate retreatment regimen?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: A — Sofosbuvir/velpatasvir/voxilaprevir 12 weeks

DAA treatment failure with NS5A resistance (Y93H) in genotype 3 with cirrhosis requires a salvage regimen. Sofosbuvir/velpatasvir/voxilaprevir (Vosevi) for 12 weeks is the recommended retreatment for patients who have failed an NS5A inhibitor-containing regimen. Adding ribavirin may be considered for genotype 3 with cirrhosis. SVR rates for retreatment are 90-95%.

Reference: GESA – 2022 – HCV Retreatment; AASLD/IDSA 2024